Authors

TANNAZ BOVAND1, HOSSEIN VATANPOUR2*, ZAHRA MOUSAVI1

Departments

1Department of Pharmacology & Toxicology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran - Iran (IAUPS) - 2Toxicology and Pharmacology Department, School of Pharmacy, Medical Science University of Shahid Beheshti, Tehran, Iran

Abstract

Introduction: GCSF is a drug That is prescribed for growing the stimulation either in some of immune system diseases or anti- concern drug users. In this study, the researchers reflected on the GCSF’s effects on different organs in pregnant mice. Then, using safe doses for mother and fetus, it was applied either as a growing stimulator or a neutralizer factor for negative effects of such tera- togenicity drugs as Phenobarbital. Using Phenobarbital during pregnancy can increase the possibility of abnormalities in infants like cleft palate, heart abnormalities and weight reduction in birthday. The purpose of this research is Studying the possible protecti- ve effect of GCSF against teratogenic effects of Phenobarbital in mice fetus.

Method: 120 mg/kg of Phenobarbital within GCSF in different doses was injected to the mice on 9th day of gestation. Their fetuses were then brought out of uterus on 15th day of gestation and were examined by microscopic and macroscopic methods.

Findings: Although it was observed that 1.63 μg/mL of GCSF amended the cleft palate in mice fetus (P<0.05), other doses of GCSF (3.25, 7.75, 12, 15μg/mL) yielded no difference in the cleft palate occurrence or its amendment in mice fetus.

Results: The results of the present study showed that GCSF may have the teratogenicity effects of Phenobarbital in cleft palate and will prevent its occurrence.

Keywords

GCSF, Phenobarbital, prevention, mice fetuswith language disorders

DOI:

10.19193/0393-6384_2017_3s_211